1. Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, Yeo W, Payne N:
A systematic review and economic evaluation of statins for the prevention of coronary events. Health technology assessment (Winchester, England) 2007, 11(14):1-160, iii-iv.
2. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002,
106(25):3143-3421.
3. Sudhop T, Lutjohann D, Kodal A, Igel M, Tribble DL, Shah S, Perevozskaya I, von Bergmann K: Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002, 106(15):1943-1948.
4. Kosoglou T, Meyer I, Veltri EP, Statkevich P, Yang B, Zhu Y, Mellars L, Maxwell SE, Patrick JE, Cutler DL et al: Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. British journal of clinical pharmacology 2002, 54(3):309-319.
5. Liyanage KE, Burnett JR, Hooper AJ, van Bockxmeer FM: Familial
hypercholesterolemia: epidemiology, Neolithic origins and modern geographic distribution. Critical reviews in clinical laboratory sciences 2011, 48(1):1-18.
6. Bell DA, Hooper AJ, Watts GF, Burnett JR: Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia. Vascular health and risk management 2012, 8:651-659.
7. Müller C: Xanthomata, Hypercholesterolemia, Angina Pectoris. Acta Medica Scandinavica 1938, 95(S89):75-84.
8. Khachadurian AK: The inheritance of essential familial hypercholesterolemia.
The American journal of medicine 1964, 37:402-407.
9. Seftel HC, Baker SG, Sandler MP, Forman MB, Joffe BI, Mendelsohn D, Jenkins T, Mieny CJ: A host of hypercholesterolaemic homozygotes in South Africa. British medical journal 1980, 281(6241):633-636.
10. Fahed AC, Safa RM, Haddad FF, Bitar FF, Andary RR, Arabi MT, Azar ST, Nemer G: Homozygous familial hypercholesterolemia in Lebanon: a genotype/phenotype correlation. Molecular genetics and metabolism 2011, 102(2):181-188.
11. Moorjani S, Roy M, Gagne C, Davignon J, Brun D, Toussaint M, Lambert M, Campeau L, Blaichman S, Lupien P: Homozygous familial
hypercholesterolemia among French Canadians in Quebec Province.
Arteriosclerosis (Dallas, Tex) 1989, 9(2):211-216.
12. Raal FJ, Pilcher GJ, Panz VR, van Deventer HE, Brice BC, Blom DJ, Marais AD: Reduction in mortality in subjects with homozygous familial
hypercholesterolemia associated with advances in lipid-lowering therapy.
Circulation 2011, 124(20):2202-2207.
13. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, Visseren FL, Sijbrands EJ, Trip MD, Stein EA et al: Simvastatin with or without ezetimibe in familial hypercholesterolemia. The New England journal of medicine 2008, 358(14):1431-1443.
14. Goldberg AC, Hopkins PN, Toth PP, Ballantyne CM, Rader DJ, Robinson JG, Daniels SR, Gidding SS, de Ferranti SD, Ito MK et al: Familial
hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. Journal of clinical lipidology 2011, 5(3):133-140.
15. Minhas R, Humphries SE, Qureshi N, Neil HA: Controversies in familial hypercholesterolaemia: recommendations of the NICE Guideline
Development Group for the identification and management of familial
hypercholesterolaemia. Heart (British Cardiac Society) 2009, 95(7):584-587;
discussion 587-591.
16. Hamilton-Craig I, Kostner K, Colquhoun D, Woodhouse S: Combination therapy of statin and ezetimibe for the treatment of familial
hypercholesterolemia. Vascular health and risk management 2010, 6:1023-1037.
17. Avellone G, Di Garbo V, Guarnotta V, Scaglione R, Parrinello G, Purpura L, Torres D, Campisi D: Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia. International angiology : a journal of the International Union of Angiology 2010, 29(6):514-524.
18. Gagne C, Gaudet D, Bruckert E: Efficacy and safety of ezetimibe
coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 2002, 105(21):2469-2475.
19. Robinson JG, Davidson MH: Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction. Expert review of cardiovascular therapy 2006, 4(4):461-476.
20. Thompsen J, Thompson PD: A systematic review of LDL apheresis in the treatment of cardiovascular disease. Atherosclerosis 2006, 189(1):31-38.
21. Thompson GR: Lipoprotein apheresis. Current opinion in lipidology 2010, 21(6):487-491.
22. Moini M, Mistry P, Schilsky ML: Liver transplantation for inherited metabolic disorders of the liver. Current opinion in organ transplantation 2010,
15(3):269-276.
23. 藥品給付規定：第 2 節心臟血管及腎臟藥物. 2.6.降血脂藥物 Drugs used for dyslipidemia. 行政院衛生署中央健康保險局.衛生福利部中央健康保險 署.
http://www.nhi.gov.tw/webdata/webdata.aspx?menu=21&menu_id=713&WD _ID=849&webdata_id=2919. Accessed February 19, 2016.
24. 「適用罕見疾病防治及藥物法之藥物品項」修正草案. Available from:
http://www.fda.gov.tw/TC/newsContent.aspx?id=10660&chk=37cbddea-dec5-49df-9bf1-c3c945a93561¶m=pn%3D6%26cid%3D3%26cchk%3D46552 e96-810a-42c3-83e1-bd5e42344633#.UyAbPCwVF9B Accessed February 19, 2016.
25. Blagden MD, Chipperfield R: Efficacy and safety of ezetimibe co-administered with atorvastatin in untreated patients with primary
hypercholesterolaemia and coronary heart disease. Current medical research and opinion 2007, 23(4):767-775.
26. 衛生福利部食品藥物管理署. 西藥、醫療器材、化粧品許可證查詢.
Available from:
http://www.fda.gov.tw/MLMS/(S(ejyfg32p1fuxjz55ywrqbl45))/H0001D.aspx?
Type=Lic&LicId=02024058 Accessed February 19, 2016.
27. PBAC. Date of PBAC Consideration: July 2013. Ezetimibe and Atorvastatin, pack containing 30 tablets ezetimibe 10 mg, and 30 tablets atorvastatin (as calcium) 10 mg, 20 mg, 40 mg or 80 mg, Atozet® Composite Pack - July 2013.
Available from:
http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2013-07/ezetimibe Accessed February 19, 2016.
28. 健保用藥品項查詢作業網頁. 行政院衛生福利部中央健康管理署
http://www.nhi.gov.tw/query/query1.aspx?menu=21&menu_id=713&webdata _id=3510&WD_ID=851 Accessed February 19, 2016.
29. Bays HE, Chen E, Tomassini JE, McPeters G, Polis AB, Triscari J: Fixed-dose combination ezetimibe+atorvastatin lowers LDL-C equivalent to
co-administered components in randomized trials: use of a dose-response model. Fundamental & clinical pharmacology 2015, 29(2):209-218.
30. PBAC. Date of PBAC Consideration: July 2012. Ezetimibe and Atorvastatin, pack containing 30 tablets ezetimibe 10 mg, and 30 tablets atorvastatin 10 mg (as calcium), atorvastatin 20 mg (as calcium), atorvastatin 40 mg (as calcium) or atorvastatin 80 mg (as calcium). Available from:
http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2012-11/ezetimibe-atorvastatin Accessed February 19, 2016.
31. Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R, Sun S, LeBeaut AP, Sager PT, Veltri EP: Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003, 107(19):2409-2415.
32. Knopp RH: Drug treatment of lipid disorders. The New England journal of medicine 1999, 341(7):498-511.
33. Cruz-Fernandez JM, Bedarida GV, Adgey J, Allen C, Johnson-Levonas AO, Massaad R: Efficacy and safety of ezetimibe co-administered with ongoing atorvastatin therapy in achieving low-density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease. International journal of clinical practice 2005, 59(6):619-627.
34. Yu CC, Lai WT, Shih KC, Lin TH, Lu CH, Lai HJ, Hanson ME, Hwang JJ:
Efficacy, safety and tolerability of ongoing statin plus ezetimibe versus doubling the ongoing statin dose in hypercholesterolemic Taiwanese patients:
an open-label, randomized clinical trial. BMC research notes 2012, 5:251.
35. PBAC. Date of PBAC Consideration: November 2014. Ezetimibe +
atorvastatin fixed dose combination tablets; 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg and 10 mg/80 mg; Atozet® - November 2014. Available from:
http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2014-11/atorvastatin-ezetimibe-psd-11-2014 Accessed March 11, 2016.
36. Laires PA, Ejzykowicz F, Hsu T-Y, Ambegaonkar B, Davies G.
Cost–effectiveness of adding ezetimibe to atorvastatin vs switching to rosuvastatin therapy in Portugal. Journal of medical economics 2015; 18(8):
565-572.
37. Kohli M, Attard C, Lam A, et al. Cost effectiveness of adding ezetimibe to atorvastatin therapy in patients not at cholesterol treatment goal in Canada.
PharmacoEconomics 2006; 24(8): 815-830.
38. Cook JR, Yin D, Alemao E, et al. Cost-effectiveness of ezetimibe coadministration in statin-treated patients not at cholesterol goal.
PharmacoEconomics 2004; 22(3): 49-61.
39. 103 年醫療統計年報. 衛生福利部.